Log In
BCIQ
Print this Print this
 

PB01

  Manage Alerts
Collapse Summary General Information
Company Paranta Biosciences Ltd.
DescriptionRecombinant human follistatin
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today